|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-10-7
|
|
pubmed:abstractText |
Uveitis is a severe manifestation of rheumatic diseases since it can lead to visual impairment and even blindness. Ocular involvement is frequently a clinical challenge because its occurrence often requires changes of the therapeutic strategy. There are growing evidence that tumor necrosis factor alpha (TNFalpha) inhibitors may be an effective treatment of refractory uveitis. Purpose of this study was to evaluate the efficacy and safety of TNFalpha blocking agents in patients with seronegative spondylo-arthropathies (SNSA) and Behcet disease (BD) associated relapsing uveitis.
|
|
pubmed:language |
ita
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfasalazine,
http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/infliximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0048-7449
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
185-9
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:15470524-Adolescent,
pubmed-meshheading:15470524-Adult,
pubmed-meshheading:15470524-Antibodies, Monoclonal,
pubmed-meshheading:15470524-Behcet Syndrome,
pubmed-meshheading:15470524-Cyclosporine,
pubmed-meshheading:15470524-Drug Resistance,
pubmed-meshheading:15470524-Drug Therapy, Combination,
pubmed-meshheading:15470524-Female,
pubmed-meshheading:15470524-Humans,
pubmed-meshheading:15470524-Immunoglobulin G,
pubmed-meshheading:15470524-Immunosuppressive Agents,
pubmed-meshheading:15470524-Male,
pubmed-meshheading:15470524-Methotrexate,
pubmed-meshheading:15470524-Middle Aged,
pubmed-meshheading:15470524-Prospective Studies,
pubmed-meshheading:15470524-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:15470524-Recurrence,
pubmed-meshheading:15470524-Remission Induction,
pubmed-meshheading:15470524-Spondylarthropathies,
pubmed-meshheading:15470524-Sulfasalazine,
pubmed-meshheading:15470524-Treatment Outcome,
pubmed-meshheading:15470524-Tumor Necrosis Factor-alpha,
pubmed-meshheading:15470524-Uveitis, Anterior,
pubmed-meshheading:15470524-Uveitis, Posterior
|
|
pubmed:articleTitle |
[The treatment of recurrent uveitis with TNF-alpha inhibitors].
|
|
pubmed:affiliation |
DIMIMP--Sezione di Reumatologia, Università degli studi di Bari, Bari.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract
|
